Larimar Therapeutics Future Growth
Future criteria checks 0/6
Larimar Therapeutics's earnings are forecast to decline at 12.3% per annum while its annual revenue is expected to grow at 59.3% per year. EPS is expected to decline by 4.8% per annum. Return on equity is forecast to be -61.5% in 3 years.
Key information
-12.3%
Earnings growth rate
-4.8%
EPS growth rate
| Biotechs earnings growth | 23.5% |
| Revenue growth rate | 59.3% |
| Future return on equity | -61.5% |
| Analyst coverage | Low |
| Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Larimar under pressure as FDA puts clinical hold on CTI-1601 program
May 26Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08
Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Dec 15Larimar completes dosing in Friedreich’s Ataxia, provides program update
Dec 08Larimar Therapeutics (LRMR) Investor Presentation - Slideshow
Nov 16Larimar Therapeutics reports Q3 results
Nov 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 52 | -173 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -144 | N/A | N/A | 4 |
| 12/31/2024 | N/A | -80 | N/A | N/A | 5 |
| 12/31/2023 | N/A | -37 | -34 | -33 | N/A |
| 9/30/2023 | N/A | -33 | -31 | -31 | N/A |
| 6/30/2023 | N/A | -33 | -27 | -27 | N/A |
| 3/31/2023 | N/A | -33 | -28 | -28 | N/A |
| 12/31/2022 | N/A | -35 | -28 | -28 | N/A |
| 9/30/2022 | N/A | -35 | -29 | -29 | N/A |
| 6/30/2022 | N/A | -44 | -36 | -35 | N/A |
| 3/31/2022 | N/A | -47 | -39 | -38 | N/A |
| 12/31/2021 | N/A | -51 | -42 | -42 | N/A |
| 9/30/2021 | N/A | -56 | -44 | -44 | N/A |
| 6/30/2021 | N/A | -49 | -43 | -43 | N/A |
| 3/31/2021 | N/A | -48 | -44 | -44 | N/A |
| 12/31/2020 | N/A | -42 | -42 | -42 | N/A |
| 9/30/2020 | N/A | -34 | -40 | -40 | N/A |
| 6/30/2020 | N/A | -33 | -35 | -35 | N/A |
| 3/31/2020 | N/A | -25 | -26 | -26 | N/A |
| 12/31/2019 | N/A | -23 | -23 | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LRMR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LRMR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LRMR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LRMR is forecast to have no revenue next year.
High Growth Revenue: LRMR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LRMR is forecast to be unprofitable in 3 years.